Source comparison
Tesamorelin NASH Support Complete Guide 2026: Comparison Table
Before initiating any peptide protocol for metabolic research, understanding mechanism-specific differences matters as much as efficacy data. | Intervention | Mechanism of Action | Mean Hepatic Fat Reduction (Clinical Trials) | Impact on Visceral Fat | Durabil
This comparison does not assign a generated winner or score.
- Before initiating any peptide protocol for metabolic research, understanding mechanism-specific differences matters as much as efficacy data.
- | Intervention | Mechanism of Action | Mean Hepatic Fat Reduction (Clinical Trials) | Impact on Visceral Fat | Durability After Discontinuation | Key Limitation | Professional Assessment ||—|—|—|—|—|—|| Tesamorelin 2mg daily | GHRH analog → pulsatile GH release → VAT lipolysis | 28–37% at 12 months | −15–18% VAT by MRI | 50% rebound within 6 months | No direct anti-fibrotic effect; glucose monitoring required | Best evidence for targeted VAT reduction in metabolic disease; requires continuous use || Semaglutide 2.4mg weekly | GLP-1 receptor agonist → appetite suppression, delayed gastric emptying | 23–31% at 48 weeks (NASH trials) | −8–12% VAT (secondary to total weight loss) | 60–70% weight regain within 12 months | Mechanism dependent on caloric deficit maintenance | Superior for total body weight reduction; hepatic benefit linked to weight loss || Vitamin E 800 IU daily | Antioxidant → reduces oxidative stress and lipid peroxidation | 15–20% at 96 weeks (PIVENS trial) | Minimal effe